U.S., June 7 -- ClinicalTrials.gov registry received information related to the study (NCT07009145) titled 'QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC' on May 28.
Brief Summary: This is a single-arm, multi-center, exploratory study evaluating the efficacy and safety of iparomlimab and tuvonralimab (QL1706) in combination with bevacizumab for the treatment of patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic colorectal cancer. Eligible participants who meet the inclusion and exclusion criteria will provide written informed consent and receive QL1706 at 5.0 mg/kg and bevacizumab at 7.5 mg/kg on Day 1 of every 3-week cycle (Q3W), until disease progre...